Relief Therapeutics (OTC: RLFTF) primed for growth; Investors are bullish

Relief Therapeutics (OTC: RLFTF), a little known company focusing on new approaches and treatments for COVID-19 and respiratory diseases with proprietary and in-licensed compounds.

The FDA granted expanded access protocol for treatment of Respiratory Failure in COVID-19 with RLF-100 (Aviptadil). Aviptadil is the first coronavirus therapeutic to demonstrate the ability to block replication of the virus in human lung cells and monocytes, while at the same time preventing synthesis of cytokines in the lungs.

Aviptadil has been granted FDA Fast Track Designation and emergency use IND authorization and is showing excellent results with a number of coronavirus patients showing significant recoveries after several days of treatment.

According to an abstract published by The Lancet, RFL-100 shows dramatic results in COVID-19 patients. So far, 19 of 21 patients have survived. Improved radiographic appearance was seen in both lungs of 17 patients and in one lung of 2 patients. A mean 292% increase in PaO2:FiO2 ratio was seen with complete remission from respiratory failure in 9 patients and ongoing improvement in 10. Seven patients were discharged from the hospital, 7 sent to intermediate care, and 5 remain in the ICU.

Three of 5 patients on ECMO have been decannulated and two have been discharged. A 75% (95% CI±3%: P<.001) reduction in IL-6 was seen with corresponding decrease in C-reactive protein. A median 4 point reduction in the NIAID Ordinal Scale was observed (P<.01).  

The short term outcomes in these 21 patients represent a dramatic response in patients who are excluded from all other trials of COVID-19 therapeutics. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect.

Relief Therapeutics (OTC: RLFTF) files SamiAir trademark

The trademark filed on Sept 14 could indicate their inhalant based version of the drug in partnership with NeuroRX. RLF-100/Aviptadil is currently tackling ARDS in COVID-19 patients.

Is Relief Therapeutics (OTC: RLFTF) a good investment?

Shares of Relief Therapeutics (OTC: RLFTF) appear to be a very good investment option, the Money Midnight Indicator is expecting its price to increase considerably in the next several months. The majority of the metrics point to this investment being highly attractive.

👆 Sign up now and don’t miss these hot stock picks!

We don’t spam!

Default image
Jay Lorrence
Investor of 12 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research.
Articles: 230